Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2019, XLVI/271: 030-031 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2019, XLVI/271: 030-031

Title: PROTEFLAZID®: clinical studies as evidence base of its antiviral activity 

Authors: Matyash V, Grynevych O, Broun T.

More details

06/271

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN ENGLISH.

PROTEFLAZID®: clinical studies as evidence base of its antiviral activity


Matyash V 1, Grynevych O2, Broun T2.

1State Institution “L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases” of the Academy of Medical Science of Ukraine, Kyiv, Ukraine; 2Scientific and Manufacturing Company Ecopharm Ltd, Kyiv, Ukraine

The article contains the results of many years of clinical studies of efficiency and safety of the preparation Proteflazid®, obtained from the wild cereals Deschampsia caespitosa L. and Calamagrotis epigeios L. Proteflazid® has direct antiviral and anti-relapsing effects in various disease of viral etiology, registered in more than 230 clinical studies.

Key words: Proteflazid®, clinical studies, flu, ARVI, herpes (HHV), papillomavirus (HPV), hepatitis, HIV-infection

Pol Med J, 2019; XLVI (271); 30–31